|NASDAQ: ENTA||Healthcare / Biotechnology / USA|
|40.07||+0.4700||+1.19%||Vol 142.40K||1Y Perf -41.57%|
|Mar 24th, 2023 16:00 DELAYED|
|- -||- -%|
|Target Price||72.10||Analyst Rating||Moderate Buy 1.89|
|Potential %||79.94||Finscreener Ranking||★★ 46.07|
|Insiders Trans % 3/6/12 mo.||-/-100/-100||Value Ranking||★★★ 50.37|
|Insiders Value % 3/6/12 mo.||-/-100/-100||Growth Ranking||★+ 40.86|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||5.92||Earnings Rating||Strong Buy|
|Market Cap||836.90M||Earnings Date||8th May 2023|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Valuation||Value||Industry||S&P 500||US Markets|
|Financial Strength||Value||Industry||S&P 500||US Markets|
|Profitability||Value||Industry||S&P 500||US Markets|
|Revenue||Value||Industry||S&P 500||US Markets|
|Dividends||Value||Industry||S&P 500||US Markets|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||8th May 2023|
|Estimated EPS Next Report||-1.91|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||247.19K|
|Avg. Monthly Volume||195.04K|
|Avg. Quarterly Volume||162.73K|
Enanta Pharmaceuticals Inc. (NASDAQ: ENTA) stock closed at 40.07 per share at the end of the most recent trading day (a 1.19% change compared to the prior day closing price) with a volume of 142.40K shares and market capitalization of 836.90M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 141 people. Enanta Pharmaceuticals Inc. CEO is Jay R. Luly.
The one-year performance of Enanta Pharmaceuticals Inc. stock is -41.57%, while year-to-date (YTD) performance is -13.87%. ENTA stock has a five-year performance of -50.34%. Its 52-week range is between 37.59 and 79.495, which gives ENTA stock a 52-week price range ratio of 5.92%
Enanta Pharmaceuticals Inc. currently has a PE ratio of -8.40, a price-to-book (PB) ratio of 3.22, a price-to-sale (PS) ratio of 16.77, a price to cashflow ratio of 154.60, a PEG ratio of 2.32, a ROA of -32.59%, a ROC of -30.48% and a ROE of -36.91%. The company’s profit margin is -81.96%, its EBITDA margin is -142.50%, and its revenue ttm is $58.51 Million , which makes it $2.81 revenue per share.
Of the last four earnings reports from Enanta Pharmaceuticals Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-1.91 for the next earnings report. Enanta Pharmaceuticals Inc.’s next earnings report date is 08th May 2023.
The consensus rating of Wall Street analysts for Enanta Pharmaceuticals Inc. is Moderate Buy (1.89), with a target price of $72.1, which is +79.94% compared to the current price. The earnings rating for Enanta Pharmaceuticals Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Enanta Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Enanta Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 7.17, ATR14 : 2.09, CCI20 : -125.89, Chaikin Money Flow : -0.29, MACD : -2.44, Money Flow Index : 31.86, ROC : -15.05, RSI : 23.53, STOCH (14,3) : 13.24, STOCH RSI : 0.42, UO : 33.24, Williams %R : -86.76), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Enanta Pharmaceuticals Inc. in the last 12-months were: Jay R. Luly (Option Excercise at a value of $790 678), Jay R. Luly (Sold 27 912 shares of value $1 260 628 ), Nathalie Adda (Option Excercise at a value of $3 386 446), Nathalie Adda (Sold 83 344 shares of value $5 967 688 ), Paul J. Mellett (Option Excercise at a value of $139 652), Paul J. Mellett (Sold 5 000 shares of value $268 816 )
|Analyst Ratings||Current||1 M ago||3 M ago|
|Summary Rating||Moderate Buy||Moderate Buy||Moderate Buy|
Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
CEO: Jay R. Luly
Telephone: +1 617 607-0800
Address: 500 Arsenal Street, Watertown 02472, MA, US
Number of employees: 141
Wed, 22 Mar 2023 16:32 GMT Analysts Offer Insights on Healthcare Companies: Enanta Pharmaceuticals (ENTA), Orgenesis (ORGS) and BELLUS Health (BLU)- TipRanks. All rights reserved.
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.